Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALS 205

Next Previous
Drug Profile

ALS 205

Alternative Names: ALS-205; PMX-205

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Queensland
  • Developer Alsonex Pharmaceuticals; University of Queensland
  • Class Anti-inflammatories; Antidementias; Cinnamates; Cyclic peptides; Indoles
  • Mechanism of Action Complement C5a inhibitors; Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Motor neuron disease; Parkinson's disease
  • Preclinical Alzheimer's disease; Huntington's disease
  • No development reported Amyotrophic lateral sclerosis
  • Discontinued Age-related macular degeneration; Autoimmune disorders; Inflammatory bowel diseases

Most Recent Events

  • 15 Dec 2023 ALS 205 is still in phase I trials for Motor neuron disease (In volunteers) in Australia (SC, Injection)
  • 15 Dec 2023 ALS 205 is still in phase I trials for Parkinson's-disease(In volunteers) in Australia (SC, Injection)
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Motor-neuron-disease(In volunteers) in Australia (SC, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top